Anti-Human FZD Recombinant Antibody
-
产品编号
YR1315
-
别名
科研级 Vantictumab ( 万替妥单抗 ), Anti-FZD Recombinant Antibody, Research Grade Vantictumab
-
规格
- 1mg
- 5mg
产品介绍
| Alias | 科研级 Vantictumab ( 万替妥单抗 ), Anti-FZD Recombinant Antibody, Research Grade Vantictumab |
| Catalog Number | YR1315 |
| Molecular Name | Vantictumab |
| CAS Number | 1345009-45-1 |
| Target | FZD[Homo sapiens] |
| Antibody Isotype | IgG2 Lambda |
| Clonity | Monoclonal |
| Size | 1mg, 5mg |
| Concentration | 1mg/ml |
| Purity | >95% as determined by SDS-PAGE |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Formulation | PBS, pH7.5 |
| Shipping Condition | Shipped on ice packs. |
| Background | Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer. This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer. OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab. |
| Application | Inhib, FCM |
| Remarks | This product is for research use only. |
- 联系我们
- 电话：400-621-6806
- 手机：13116038708
- 邮箱：info@kmdbioscience.com
- 地址：天津市武清区国际企业社区A5栋
-
销售微信
-
官方公众号
-
400-621-6806 -
614353794 -
周一至周五 8:30-18:00 -
-
0
-
